SynthesisFrontiers in oncology2025
Prognostic effect of pretreatment serum gamma-glutamyl transferase in urological malignancies: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preoperative gamma-glutamyl transferase to lymphocyte ratio predicts recurrence in non-muscle-invasive bladder cancer.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to investigate the association between pretreatment serum gamma-glutamyltransferase (GGT) and survival outcomes in patients with urological malignancies, such as urothelial carcinoma (UCa), renal cell carcinoma (RCC), and prostate cancer (PCa). Methods: A comprehensive literature search was conducted in PubMed, Ovid, Web of Science, and the Cochrane Library up to December 2024. Survival outcomes were analyzed through the computation of merged hazard ratios (HRs) and 95% confidence intervals (CIs) using Stata 18.0 software. Results: Ten studies involving 2,817 patients were included in the final analysis. The results indicated that elevated pretreatment serum GGT demonstrated a significant association with poorer overall survival (OS) (HR = 3.32, 95% CI: 2.51-4.39), cancer-specific survival (CSS) (HR = 1.95, 95% CI: 1.26-3.04), and progression-free survival (PFS) (HR = 2.34, 95% CI: 1.72-3.17). Subgroup analyses stratified by cancer type demonstrated that elevated serum GGT served as a significant predictor of OS in UCa (HR 3.11, 95% CI 2.08-4.65), RCC (HR 3.51, 95% CI 2.27-5.43), and PCa (HR 3.61, 95% CI 1.51-8.62). Consistent associations were observed for CSS (Uca: HR 1.88, 95% CI 1.23-2.88) and PFS (Uca: HR 2.58, 95% CI 1.24-3.93; RCC: HR 2.00, 95% CI 1.28-3.13; PCa: HR 2.90, 95% CI 1.34-6.26). No significant publication bias was detected across the included studies. Conclusions: Pretreatment serum GGT served as an independent predictor of OS, CSS, and PFS in urological malignancies, suggesting that it may be a potential prognostic factor in clinical practice. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42025629976, identifier CRD42025629976.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.